Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Banking vet Ross McEwan selected as new BHP chair

(Sharecast News) - BHP has announced that its chair of eight years, Ken MacKenzie, is to retire from the board at the end of next month and will be replaced by banking veteran and former RBS boss Ross McEwan. MacKenzie is to step down on 31 March, having joined the board in September 2016 and been chair since September 2017. During his tenure, he is said to have overseen the strategic transformation of BHP's portfolio towards future-facing commodities.

""It has been a privilege to serve as the chair of BHP for the last eight years and as a director for nine years and I am proud of what the board and management has achieved during that time," MacKenzie said in a statement.

"Ross is an excellent choice as leader of the board, and I wish him every success in the role."

McEwan, who has served as independent non-executive director since April of last year, has more than 30 years' global executive experience, particularly in the financial services industry, having worked as the CEO of National Australia Bank from 2019 to 2024 and CEO of the Royal Bank of Scotland from 2013 to 2019.

He has also held executive roles at Commonwealth Bank of Australia, First NZ Capital Securities and National Mutual Life Association of Australasia / AXA New Zealand.

"As incoming chair, I am committed to generating long-term value for all our shareholders and will work tirelessly with the board and management to achieve this. I look forward to continuing to take this great company forward," McEwan said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.